Results for tag: "Flucelvax QIV"

Flucelvax QIV is a quadrivalent inactivated influenza vaccine (QIV) used to protect against four strains of influenza virus. It is approved for use in adults 18 years of age and older. It is administered as a single dose, either intramuscularly or subcutaneously. The vaccine is designed to provide protection against two influenza A strains and two influenza B strains. It is recommended for use in individuals who are at high risk of developing serious complications from influenza, such as pregnant women, people with chronic medical conditions, and those over 65 years of age. The Flucelvax QIV market is a subset of the larger vaccine market, which is a rapidly growing industry. Vaccines are used to prevent and treat a wide range of infectious diseases, and the global demand for vaccines is increasing due to the rising prevalence of infectious diseases. The Flucelvax QIV market is expected to benefit from the increasing demand for vaccines, as well as the growing awareness of the importance of influenza vaccination. Some of the companies in the Flucelvax QIV market include Seqirus, Sanofi Pasteur, GlaxoSmithKline, Merck, and Pfizer. Show Less Read more